Remus Pharmaceuticals
- Market cap
- ₹ 1,043 Cr.
- P/E
- 27.9x
- P/B
- 3.03x
- 52-week range
- 580 – 1,039
- ROE
- 12%
- ROCE
- 17%
- Dividend yield
- 0.1%
- Debt / equity
- 0.08
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE SME
About
Remus Pharmaceuticals Limited is an India-based company, which is engaged in marketing and distribution of finished formulations of pharmaceutical drugs. The Company also deals in active pharmaceutical ingredients (APIs). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. It offers a range of pharmaceutical formulations and products manufactured on contract manufacturing and on a loan license basis. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension and tablet. The Company offers its products in various therapeutic categories, such as oncology, cardiovascular, anti-diabetic, central nervous system (CNS), immunosuppressants, anti-biotic - antibacterial and dermatology.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Remus Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)27.9 against a typical 34.3: cheaper than most peers (1st = cheapest).93rd of 220
- Sales growth+144.9% against a typical +15.6% from a year earlier.11th of 197
- Profit growth+31.6% against a typical +18.9% from a year earlier.67th of 160
- Share price, 3 months+22.3% against a typical −0.5%.32nd of 200
- Size₹ 1,042.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).87th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 20 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the audited financial results for the period ended March 31, 2026, recommend final dividend, if any and other business matters |
| 10 Nov 2025 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended September 30, 2025, dividend and other business matters |
| 17 May 2025 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters |
| 9 Nov 2024 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended September 30, 2024, interim dividend and other business matters |
| 16 May 2024 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2024 and other business matters |
| 23 Apr 2024 | REMUS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 23-Apr-2024 to consider and approve Dividend/Bonus/Increase in authorised capital/Other business. | Board Meeting Intimation |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 29 | 185 | 273 | 348 | 400 | 453 |
| Expenses | 20 | 165 | 252 | 323 | 373 | 424 |
| Operating Profit | 9 | 20 | 20 | 25 | 27 | 30 |
| OPM % | 32% | 11% | 8% | 7% | 7% | 7% |
| Other Income | 2 | 3 | 3 | 3 | 3 | 4 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 |
| Profit before tax | 10 | 22 | 22 | 25 | 28 | 31 |
| Tax % | 25% | 15% | 16% | 19% | 23% | 21% |
| Net Profit | 6 | 19 | 19 | 21 | 22 | 25 |
| EPS in Rs | 4.87 | 13.16 | 11.87 | 13.57 | 14.85 | 16.54 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 38%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 28%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 13%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Remus Pharmaceuticals | ₹ 879.00 | ₹ 1,043 Cr. | 27.9x | 3x | 12% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Anjali Shah
- Chief Financial Officer
- Deval Bakulkumar Patel
- Compliance Officer, Company Secretary
- Arpit Deepakkumar Shah
- Managing Director, Executive Director
- Roma Vinodbhai Shah
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.